TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02531464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
Study: NCT00694629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin
Description: tablet, 10 mg/kg, daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine
Description: tablet, 10 mg/kg, daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine
Description: tablet, 15 mg/kg, daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine
Description: 20 mg/kg, daily, 8 weeks
Study: NCT00595413

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
Study: NCT02058485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midazolam
Description: Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
Study: NCT03111550

Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational Intraocular Lens Device #1: TECNIS Model ZHR00
Description: Intraocular lens replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational Intraocular Lens Device #2: TECNIS Model ZQR00
Description: Intraocular lens replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
Description: Intraocular lens replaces the natural lens removed during cataract surgery.
Study: NCT02252575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic field
Description: Exposure to the electromagnetic fields of electric motors
Study: NCT03128385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive CIT Model Program
Description: Day Camp Model:~1. The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distributed CIT Model Program
Description: Home-Based Model:~1. The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand
Study: NCT04007601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
Study: NCT01271387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO single dose
Study: NCT02732353

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Minced beef
Description: Cow meat protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed beef
Description: Cow meat protein supplement
Study: NCT02603354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peroxide gel tooth bleaching 6%
Description: gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peroxide gel tooth bleaching 6%
Description: gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
Study: NCT03897868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803
Description: HCP1803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803
Description: HCP1803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803
Description: HCP1803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02793323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial cervical nerve block
Description: A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSAID
Description: 100 mg (100 ml) intravenous NSAIDs (Profenid)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: 100 ml IV saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo superficial cervical nerve block
Description: Superficial cervical nerve block containing 5 ml saline
Study: NCT01949727

Intervention type: OTHER
Intervention: AIM 2: Pulmonary Rehabilitation
Description: Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
Study: NCT01588353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
Study: NCT04208334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We give a control arm to consume placebo for 60 consecutive days.
Study: NCT03896113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg capsule
Description: Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
Study: NCT04295993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
Study: NCT01764282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive intervention components
Description: ART promotion, Couple testing and consulting promotion, and Condom use promotion
Study: NCT01078129

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive remediation therapy
Description: program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: non-CRT
Description: waiting list
Study: NCT04683419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Thoracoscopic pleural Cryobiopsy
Description: Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe
Study: NCT03345394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
Study: NCT01955213

Intervention type: DRUG
Intervention: methylnaltrexone
Description: Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.

Intervention type: DRUG
Intervention: methylnaltrexone
Description: Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.

Intervention type: DRUG
Intervention: methylnaltrexone
Description: Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
Study: NCT02497118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: Endostatin,7.5mg/m\^2,intravenous, d1-14;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinorelbine,25mg/m\^2,intravenous, d1, d8;
Study: NCT02239913

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentermine
Description: The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: The pharmacodynamic effects of chronic topiramate will be determined.
Study: NCT02497118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: vinorelbine,25mg/m\^2,intravenous, d1, d8;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin，75mg/m\^2 intravenous,divide into d1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin，75mg/m\^2 intravenous,divide into d1-3
Study: NCT02681146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Educational advice + physiotherapist treatment
Study: NCT01956617

Intervention type: OTHER
Group type: OTHER
Intervention: lumbar plexus block
Study: NCT00186043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine/Seroquel
Description: Quetiapine/Seroquel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01917864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPad Application
Description: A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
Study: NCT03835221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A toric contact lenses
Description: Bilateral daily wear of methafilcon A toric contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A toric contact lenses
Description: Bilateral daily wear of fanfilcon A toric contact lenses
Study: NCT01254474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac chambers mapping with MAP 4
Study: NCT01131793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerAssert RF wire in crossing coronary in-stent chronic total occlusions
Description: Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
Study: NCT03187366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bottom-up intervention
Description: Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bottom-up intervention
Description: Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
Study: NCT02015689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits to Child
Description: CDC VIS + message emphasizing benefits to child of MMR vaccine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits to Society
Description: CDC VIS + message emphasizing benefits to society of MMR vaccine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits to Child and Society
Description: CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC VIS
Description: CDC Vaccine Information Statement (VIS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC VIS
Description: CDC Vaccine Information Statement (VIS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC VIS
Description: CDC Vaccine Information Statement (VIS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC VIS
Description: CDC Vaccine Information Statement (VIS)
Study: NCT03749629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GeneSight Psychotropic test
Description: GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines
Description: Guidelines for treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines
Description: Guidelines for treatment
Study: NCT03514654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy
Description: Removal of the whole breast.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Mammoplasty
Description: Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
Study: NCT02494817

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Male Couples Agreement Project
Description: Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Male Couples Agreement Project
Description: Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
Study: NCT04076488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dividat Fit
Description: tablet based, remote assisted home-training
Study: NCT01785121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured access to a Wii game computer (Wii)
Description: Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational support only
Description: The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks